Patient Reporting Encouraged during Monitoring of Dapoxetine in New Zealand

ISSN： 0114-5916

Source： Drug Safety, Vol.34, Iss.11, 2011-11, pp. : 1115-1116

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation

By Kowey Peter R.

Drugs in R&D, Vol. 11, Iss. 1, 2011-03 ,pp. : 1-11

Adis International

Access to resources Recommend Favorite

Reporting Purchasers of Pseudoephedrine Products to Police: New Zealand Community Pharmacists' Experiences

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 37, Iss. 1, 2007-03 ,pp. : 19-21

John Wiley & Sons Inc

Access to resources Recommend Favorite

Exceptional Patient Loyalty under the New Pharmacy Services Agreement in New Zealand

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 43, Iss. 4, 2013-12 ,pp. : 259-259

John Wiley & Sons Inc

Access to resources Recommend Favorite

Incidence and Costs of Adverse Drug Reactions During Hospitalisation: Computerised Monitoring Versus Stimulated Spontaneous Reporting

By Geisslinger G.

Drug Safety, Vol. 22, Iss. 2, 2000-02 ,pp. : 161-169

Adis International

Access to resources Recommend Favorite

The New Zealand (NZ) Centre for Adverse Reactions Monitoring has received 14 reports of facial skin damage

Reactions Weekly, Vol. 1, Iss. 1081, 2005-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite